CARLSBAD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming
a leading immune-based therapy company in HIV and multiple sclerosis, will
present at the Capital Growth Investor Forum. Chief Executive Officer John
N. Bonfiglio, Ph.D., will make his presentation on Thursday, November 4, 2004,
at 9:00am EST. The conference will be held at the Renaissance Hotel,
Boca Raton, FL.
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical
company dedicated to becoming a leading immune-based therapy company in HIV
and multiple sclerosis (MS). The Company's HIV products are based on its
patented whole-killed virus technology, co-invented by Company founder
Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in
Phase II clinical trials, is being developed as a first-line treatment for
people with early-stage HIV. The Company has initiated development of a new
immune-based therapy, IR103, which incorporates a second-generation
immunostimulatory oligonucleotide adjuvant and is currently in Phase I
clinical trials in Canada and the United Kingdom.
The Immune Response Corporation is also developing an immune-based therapy
for MS, NeuroVax(TM), which is currently in Phase II and has shown potential
therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation at http://www.imnr.com.
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern
and successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of
REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical
trials. These risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual Report on
Form 10-K for the year ended December 31, 2003, and any subsequent Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
For further information please contact: Media, Laura Silver of Sam Brown
Inc. Corporate Communications, +1-310-551-9940, silver@sambrown.com, for The
Immune Response Corporation; or Investor Relations, Kathy Waller of Financial
Relations Board, +1-312-266-7800, kwaller@financialrelationsboard.com, for The
Immune Response Corporation; or Michael K. Green, Chief Financial Officer of
The Immune Response Corporation, +1-760-431-7080, info@imnr.com
SOURCE Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
Company News On-Call:
http://www.prnewswire.com/comp/434675.html
CONTACT:
Media, Laura Silver of Sam Brown Inc.
Corporate Communications, +1-310-551-9940, silver@sambrown.com,
for The Immune Response Corporation; or Investor Relations, Kathy
Waller of Financial Relations Board, +1-312-266-7800,
kwaller@financialrelationsboard.com, for The Immune Response
Corporation; or Michael K. Green, Chief Financial Officer of The
Immune Response Corporation, +1-760-431-7080, info@imnr.com
|
